Ifinatamab deruxtecan for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Jun 2026: Trial registered, NCT07630974
  2. 6 Jul 2026: Trial started, NCT07630974

The trials

NCT07630974: A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

State
Under way
Phase
Phase 1 and Phase 2
People
134 planned
Started
6 Jul 2026
Primary completion
17 Aug 2031
Arms
Ifinatamab Deruxtecan
Results
None posted
  1. 5 Jun 2026: Trial registered
  2. 6 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as Ifinatamab Deruxtecan (I-DXd).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.